AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study
Now that AstraZeneca has scored its Farxiga outcomes data, it’s aiming to change the game on its SGLT2 diabetes rivals. First up? Expanding its salesforce to prepare for a full-court press on doctors. The British drugmaker aims to “increase the scope” of its physician marketing after phase 3 trial data showed Farxiga cut the risk of cardiovascular… Read More »